Since 2019, Medetia has been pioneering the exploration and development of new therapies for rare diseases. By capitalizing on strategic collaborations with prominent French research institutions such as Inserm and Imagine, Medetia excels in identifying promising academic initiatives related to rare diseases and converting them into exclusive drug candidates. This year, Medetia unveiled a strategic partnership with Ipsen, an international biopharmaceutical group, as part of the Hybridge™ research program. This initiative is dedicated to scouting potential medicinal candidates for specific rare diseases, including neurodegenerative disorders and rare pediatric genetic conditions.